Altamira Therapeutics Ltd.
CYTOF
$0.07
$0.009916.47%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 107.89% | 117.97% | -172.38% | -321.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 107.89% | 117.97% | -172.38% | -321.39% |
| Cost of Revenue | -- | -- | -- | -- | -89.91% |
| Gross Profit | -- | -- | -- | -- | 36.92% |
| SG&A Expenses | 39.97% | -14.35% | -37.89% | -88.33% | -72.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -118.84% | -163.77% | -529.27% | 204.10% | 209.87% |
| Total Operating Expenses | 751.98% | 20.30% | -39.41% | -138.54% | -94.21% |
| Operating Income | -414.43% | -14.80% | 39.35% | 140.11% | 90.02% |
| Income Before Tax | 71.67% | 74.46% | 76.89% | 58.78% | -75.18% |
| Income Tax Expenses | -- | -- | -- | 112.78% | 123.97% |
| Earnings from Continuing Operations | 71.74% | 74.48% | 76.88% | 58.09% | -79.01% |
| Earnings from Discontinued Operations | -- | 0.00% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 82.61% | 80.42% | 78.58% | 37.89% | -25.87% |
| EBIT | -414.43% | -14.80% | 39.35% | 140.11% | 90.02% |
| EBITDA | -- | 43.76% | 38.86% | 140.98% | 90.63% |
| EPS Basic | 92.63% | 91.45% | 90.72% | 62.65% | 24.40% |
| Normalized Basic EPS | -103.68% | 72.21% | 85.31% | 237.62% | 135.52% |
| EPS Diluted | 92.63% | 91.45% | 90.72% | 62.65% | 24.40% |
| Normalized Diluted EPS | -103.68% | 72.21% | 85.31% | 237.62% | 135.52% |
| Average Basic Shares Outstanding | 806.58% | 718.37% | 448.32% | 202.67% | 255.80% |
| Average Diluted Shares Outstanding | 847.86% | 780.59% | 574.67% | 339.21% | 255.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
